PMID- 31787407
OWN - NLM
STAT- MEDLINE
DCOM- 20200609
LR  - 20201110
IS  - 1879-0070 (Electronic)
IS  - 0732-8893 (Linking)
VI  - 96
IP  - 2
DP  - 2020 Feb
TI  - Impact of IVIG therapy on serologic testing for infectious diseases.
PG  - 114952
LID - S0732-8893(19)30867-3 [pii]
LID - 10.1016/j.diagmicrobio.2019.114952 [doi]
AB  - Intravenous immunoglobulin (IVIG) is used to treat an increasing number of 
      conditions. The anti-inflammatory and immunomodulatory effects of IVIG can be 
      life-saving; however, recent administration may complicate evaluation for 
      infection. To assess the impact of IVIG therapy on a variety of common viral, 
      bacterial, fungal, and parasitic serologies we prospectively evaluated serologic 
      changes pre- and post-IVIG infusion in 7 participants. The number of new antibody 
      detections ranging from 2 to 5. New detections included positivity for 
      Epstein-Barr virus early D antigen, herpes simplex virus, West Nile virus, 
      cytomegalovirus, and the endemic mycoses Histoplasma and Coccidioides. The 
      greatest number of newly positive serologies was observed in subjects receiving 
      cumulative doses of IVIG in excess of 100 g. Our results illustrate the 
      difficulty in serologic interpretation following IVIG therapy and suggest a 
      dose-response to new positive results. These findings may be a helpful resource 
      to clinicians facing similar circumstances.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Hanson, Kimberly E
AU  - Hanson KE
AD  - University of Utah School of Medicine, Salt Lake City, UT, USA.
FAU - Gabriel, Nielsen
AU  - Gabriel N
AD  - Department of Internal Medicine, Division of Infectious Diseases, University of 
      California Davis Medical Center, Davis, CA, USA.
FAU - Mchardy, Ian
AU  - Mchardy I
AD  - Department of Medical Microbiology and Immunology, University of 
      California-Davis, Davis, CA, USA.
FAU - Hoffmann, Wesley
AU  - Hoffmann W
AD  - Department of Internal Medicine, Division of Infectious Diseases, University of 
      California Davis Medical Center, Davis, CA, USA.
FAU - Cohen, Stuart H
AU  - Cohen SH
AD  - Department of Internal Medicine, Division of Infectious Diseases, University of 
      California Davis Medical Center, Davis, CA, USA.
FAU - Couturier, Marc Roger
AU  - Couturier MR
AD  - University of Utah School of Medicine, Salt Lake City, UT, USA; Associated 
      Regional and University Pathologists (ARUP), Salt Lake City, UT, USA.
FAU - Thompson, George R 3rd
AU  - Thompson GR 3rd
AD  - Department of Internal Medicine, Division of Infectious Diseases, University of 
      California Davis Medical Center, Davis, CA, USA; Department of Medical 
      Microbiology and Immunology, University of California-Davis, Davis, CA, USA. 
      Electronic address: grthompson@ucdavis.edu.
LA  - eng
PT  - Journal Article
DEP - 20191123
PL  - United States
TA  - Diagn Microbiol Infect Dis
JT  - Diagnostic microbiology and infectious disease
JID - 8305899
RN  - 0 (Antibodies, Viral)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
CIN - Diagn Microbiol Infect Dis. 2020 Apr;96(4):114986. PMID: 32008811
MH  - Adult
MH  - Aged
MH  - Antibodies, Viral/isolation & purification
MH  - Communicable Diseases/*diagnosis/*drug therapy/immunology
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/therapeutic use
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - *Serologic Tests
MH  - Treatment Outcome
OTO - NOTNLM
OT  - IVIG
OT  - Infection
OT  - Serology
EDAT- 2019/12/04 06:00
MHDA- 2020/06/10 06:00
CRDT- 2019/12/03 06:00
PHST- 2019/08/27 00:00 [received]
PHST- 2019/11/06 00:00 [revised]
PHST- 2019/11/07 00:00 [accepted]
PHST- 2019/12/04 06:00 [pubmed]
PHST- 2020/06/10 06:00 [medline]
PHST- 2019/12/03 06:00 [entrez]
AID - S0732-8893(19)30867-3 [pii]
AID - 10.1016/j.diagmicrobio.2019.114952 [doi]
PST - ppublish
SO  - Diagn Microbiol Infect Dis. 2020 Feb;96(2):114952. doi: 
      10.1016/j.diagmicrobio.2019.114952. Epub 2019 Nov 23.